Combination therapy for treating cancer
US10456407B2 · kind B2 · utility
9Cited by
2References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 20, 2016 |
| Grant date | Oct 29, 2019 |
| Priority date | — |
| Expiry date | Apr 20, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.